Persistence in patients with breast cancer treated with tamoxifen or aromatase inhibitors: a retrospective database analysis

No abstract is available for this paper.

• Publication year

  2013

• Venue

  Breast Cancer Research and Treatment

• Publication date

  2013-01-20

• Fields of study

  Medicine

• Identifiers
  DOI 10.1007/s10549-013-2417-1PMID 23334803
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Adherence to adjuvant endocrine therapy in women with breast cancer

  2013cited by this paper
• Adherence and discontinuation of adjuvant hormonal therapy in breast cancer patients: a population-based study

  2012cited by this paper
• Early discontinuation of tamoxifen intake in younger women with breast cancer: is it time to rethink the way it is prescribed?

  2012cited by this paper
• Adjuvant endocrine therapy for breast cancer.

  2012cited by this paper
• Adherence to adjuvant hormonal therapy among breast cancer survivors in clinical practice: a systematic review

  2012cited by this paper
• Krebs in Deutschland

  2012cited by this paper
• Medical Record Databases

  2012cited by this paper
• Five-year patterns of adjuvant hormonal therapy use, persistence, and adherence among insured women with early-stage breast cancer

  2011cited by this paper
• Invasive breast cancer.

  2011cited by this paper
• GRAND: the German retrospective cohort analysis on compliance and persistence and the associated risk of fractures in osteoporotic women treated with oral bisphosphonates

  2011cited by this paper
• Predictors of non-adherence to aromatase inhibitors among commercially insured women with breast cancer

  2010cited by this paper
• Estimates of cancer incidence and mortality in Europe in 2008.

  2010cited by this paper
• Improving compliance and persistence to adjuvant tamoxifen and aromatase inhibitor therapy.

  2010cited by this paper
• American Society of Clinical Oncology clinical practice guideline: update on adjuvant endocrine therapy for women with hormone receptor-positive breast cancer.

  2010cited by this paper
• Early discontinuation and nonadherence to adjuvant hormonal therapy in a cohort of 8,769 early-stage breast cancer patients.

  2010cited by this paper
• Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 10-year analysis of the ATAC trial.

  2010cited by this paper
• Breast cancer. Clinical practice guidelines in oncology.

  2009cited by this paper
• Validity and representativeness of the "Disease Analyzer" patient database for use in pharmacoepidemiological and pharmacoeconomic studies.

  2009cited by this paper
• Factors Affecting Discontinuation of Alendronate Treatment in Postmenopausal Japanese Women With Osteoporosis

  2009cited by this paper
• Clinical perspectives on the utility of aromatase inhibitors for the adjuvant treatment of breast cancer.

  2009cited by this paper
• Adherence to initial adjuvant anastrozole therapy among women with early-stage breast cancer.

  2008cited by this paper
• Interventions for enhancing medication adherence.

  2008cited by this paper
• Adherence to adjuvant endocrine therapy in postmenopausal women with breast cancer.

  2008cited by this paper
• Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 100-month analysis of the ATAC trial.

  2008cited by this paper
• Summary of aromatase inhibitor clinical trials in postmenopausal women with early breast cancer

  2008cited by this paper
• Menopausal symptoms and adjuvant therapy-associated adverse events.

  2008cited by this paper
• Interventions for enhancing medication adherence.

  2008cited by this paper
• Patient Centered Experiences in Breast Cancer: Predicting Long-Term Adherence to Tamoxifen Use

  2007cited by this paper
• Isopropanolic black cohosh extract and recurrence-free survival after breast cancer.

  2007cited by this paper
• Oncologist-patient discussion of adjuvant hormonal therapy in breast cancer: results of a linguistic study focusing on adherence and persistence to therapy.

  2007cited by this paper
• Early discontinuation of tamoxifen

  2007cited by this paper
• Comprehensive side-effect profile of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: long-term safety analysis of the ATAC trial.

  2006cited by this paper
• Estimates of the cancer incidence and mortality in Europe in 2006.

  2006cited by this paper
• Discontinuation Syndrome Associated with Paroxetine in Depressed Patients

  2006cited by this paper
• Methods for evaluation of medication adherence and persistence using automated databases

  2006cited by this paper
• Adherence to medication.

  2005cited by this paper
• The importance of medication adherence in improving chronic-disease related outcomes: what we know and what we need to further know.

  2005cited by this paper
• Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years' adjuvant treatment for breast cancer.

  2005cited by this paper
• Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials.

  2005cited by this paper
• Adherence beliefs among breast cancer patients taking tamoxifen.

  2005cited by this paper
• A checklist for retrospective database studies--report of the ISPOR Task Force on Retrospective Databases.

  2003cited by this paper
• Adherence to Long-Term Therapies: Evidence for Action

  2003cited by this paper
• Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early‐stage breast cancer

  2003cited by this paper
• Nonadherence to adjuvant tamoxifen therapy in women with primary breast cancer.

  2003cited by this paper
• Adherence to therapy with oral antineoplastic agents.

  2002cited by this paper
• Persistence with drug therapy: a practical approach using administrative claims data.

  2001cited by this paper
• Persistence with drug therapy: a practical approach using administrative claims data.

  2001cited by this paper
• Patients' beliefs about prescribed medicines and their role in adherence to treatment in chronic physical illness.

  1999cited by this paper

• Characterizing safety, toxicity, and breast cancer risk reduction using a long-term fulvestrant eluting implant

  2025cites this paper
• Reshaping Breast Cancer Survivorship Through Expanding the Indications for the Omission of Radiation

  2025cites this paper
• Experience and Coping Strategies of Endocrine Therapy‐Related Symptoms in Breast Cancer Patients: A Systematic Review and Qualitative Meta‐Synthesis

  2025cites this paper
• Standardized patient coaching improves therapy persistence in patients with hormone receptor–positive, HER2–negative advanced/metastatic breast cancer treated with abemaciclib

  2025cites this paper
• 5-year adherence to adjuvant endocrine treatment in Dutch women with early stage breast cancer: A population-based database study (2006–2016)

  2023influential citation
• Feasibility of Symptom Monitoring During the First Year of Endocrine Therapy for Early Breast Cancer Using Patient-Reported Outcomes Collected via Smartphone App

  2023cites this paper
• Investigation of Factors Affecting Adherence to Adjuvant Hormone Therapy in Early-Stage Breast Cancer Patients: A Comprehensive Systematic Review

  2023cites this paper
• A long-term fulvestrant eluting implant is safe, non-toxic, and reduces the risk of breast cancer in in vivo models

  2023cites this paper
• Adherence to Oral Anticancer Medications Among Women With Breast Cancer in Africa: A Scoping Review

  2023cites this paper
• Adherence to Adjuvant Endocrine Therapy in Breast Cancer Patients

  2023cites this paper
• Resistance to Resilience: Understanding Post-surgical Hormone Therapy in Breast Cancer Care

  2023cites this paper
• Full Compliance of Adjuvant Endocrine Therapy Is Associated with Higher Disease-Free Survival in Hormone Receptor-Positive and HER2-Negative Chinese Breast Cancer Patients with First Tumor Recurrence

  2022cites this paper
• Association of treatment-emergent symptoms identified by patient-reported outcomes with adjuvant endocrine therapy discontinuation

  2022cites this paper
• Impact of hormone therapy side effects on health-related quality of life, distress, and well-being of breast cancer survivors

  2022cites this paper
• Health-Related Quality of Life in Women With Breast Cancer Undergoing Treatment With Hormonal Therapy - A Review Study.

  2022cites this paper
• Persistence with tamoxifen and aromatase inhibitors in Germany: a retrospective cohort study with 284,383 patients

  2022cites this paper
• Influence of Glutathione-S-Transferase A1*B Allele on the Metabolism of the Aromatase Inhibitor, Exemestane, in Human Liver Cytosols and in Patients Treated With Exemestane

  2022cites this paper
• The impact of medication side effects on adherence and persistence to hormone therapy in breast cancer survivors: A quantitative systematic review

  2022cites this paper
• Association of treatment-emergent symptoms identified by patient-reported outcomes with adjuvant endocrine therapy discontinuation

  2022cites this paper
• Personalising therapy for early-stage oestrogen receptor-positive breast cancer in older women

  2022cites this paper
• Investigation of Intervention Solutions to Enhance Adherence to Oral Anticancer Medicines in Adults: Overview of Reviews

  2021cites this paper
• The impact of medication side effects on adherence and persistence to hormone therapy in breast cancer survivors: A qualitative systematic review and thematic synthesis

  2021cites this paper
• Endocrine Treatment for Breast Cancer Patients Revisited—History, Standard of Care, and Possibilities of Improvement

  2021cites this paper
• Perils of Prolonged Ovarian Suppression and Hypoestrogenism in the Treatment of Breast Cancer: Is the Risk of Treatment Worse than the Risk of Recurrence?

  2021cites this paper
• Toxicity Index, Patient-Reported Outcomes, and Early Discontinuation of Endocrine Therapy for Breast Cancer Risk Reduction in NRG Oncology/NSABP B-35

  2021cites this paper
• The role of the clinical pharmacist in guiding adjuvant hormonal therapy in patients with breast cancer

  2021cites this paper
• Association of Modifiable Risk Factors With Early Discontinuation of Adjuvant Endocrine Therapy: A Post Hoc Analysis of a Randomized Clinical Trial.

  2021cites this paper
• Further Evidence That OPG rs2073618 Is Associated With Increased Risk of Musculoskeletal Symptoms in Patients Receiving Aromatase Inhibitors for Early Breast Cancer

  2021cites this paper
• Radiation without endocrine therapy in older women with stage I estrogen-receptor (ER) positive breast cancer is not associated with a higher risk of second breast cancer events.

  2021cites this paper
• Factors influencing adherence to adjuvant endocrine therapy in breast cancer-treated women: using real-world data to inform a switch from acute to chronic disease management

  2020cites this paper
• Persistence to aromatase inhibitors in the SIDIAP cohort: mortality and influence of bisphosphonates

  2020cites this paper
• Persistencia a los inhibidores de la aromatasa en la cohorte SIDIAP: mortalidad e influencia de los bifosfonatos

  2020cites this paper
• Is the extension of adjuvant hormone therapy for breast cancer justified?

  2020cites this paper
• Clinical practice to address tamoxifen nonadherence

  2020cites this paper
• Predictors of increased risk for early treatment non-adherence to oral anti-estrogen therapies in early-stage breast cancer patients

  2020cites this paper
• Endocrine Therapy in Early Breast Cancer

  2020cites this paper
• Cardiotoxicity of Sequential Aromatase Inhibitors Use in Women with Breast Cancer.

  2020cites this paper
• Preexisting musculoskeletal burden and its development under letrozole treatment in early breast cancer patients

  2019cites this paper
• Update Breast Cancer 2019 Part 1 – Implementation of Study Results of Novel Study Designs in Clinical Practice in Patients with Early Breast Cancer

  2019cites this paper
• Prescription Refill Gap of Endocrine Treatment from Electronic Medical Records as a Prognostic Factor in Breast Cancer Patients

  2019cites this paper
• Update Mammakarzinom 2019 Teil 1 – Implementierung der Ergebnisse neuer Studienkonzepte beim frühen Mammakarzinom in die klinische Praxis

  2019cites this paper
• Influence of patient and tumor characteristics on therapy persistence with letrozole in postmenopausal women with advanced breast cancer: results of the prospective observational EvAluate-TM study

  2019cites this paper
• Predicting the Benefit of Adjuvant Aromatase Inhibitor Therapy in Postmenopausal Breast Cancer Patients with Phosphorylated S6K1 Expression Status

  2019cites this paper
• Update Mammakarzinom 2019 Teil 1 – Implementierung der Ergebnisse neuer Studienkonzepte beim frühen Mammakarzinom in die klinische Praxis

  2019cites this paper
• Update Breast Cancer 2018 (Part 2) – Advanced Breast Cancer, Quality of Life and Prevention

  2018cites this paper
• Update Mammakarzinom 2018 (Teil 2) – Fortgeschrittenes Mammakarzinom, Lebensqualität und Prävention

  2018cites this paper
• Optimal management of luminal breast cancer: how much endocrine therapy is long enough?

  2018cites this paper
• Local delivery of hormonal therapy with silastic tubing for prevention and treatment of breast cancer

  2018cites this paper
• Ageing perceptions and non-adherence to aromatase inhibitors among breast cancer survivors.

  2018cites this paper
• Influence of side-effects on early therapy persistence with letrozole in post-menopausal patients with early breast cancer: Results of the prospective EvAluate-TM study.

  2018cites this paper
• Interventions to promote adherence to endocrine therapy among breast cancer survivors: A meta‐analysis

  2018cites this paper
• Understanding adjuvant endocrine therapy persistence in breast Cancer survivors

  2018cites this paper
• Aging Perceptions and Non-Adherence to Aromatase Inhibitors among Breast Cancer Survivors

  2018cites this paper
• Influence of patient and tumor characteristics on early therapy persistence with letrozole in postmenopausal women with early breast cancer: results of the prospective Evaluate-TM study with 3941 patients

  2018cites this paper
• First-line treatment disruption among post-menopausal women with HR+/HER2– metastatic breast cancer: a retrospective US claims study

  2017cites this paper
• Autologous Fat Grafting as a Novel Antiestrogen Vehicle for the Treatment of Breast Cancer

  2017cites this paper
• Breast Cancer Survivors And Medication Adherence: The Role Of Health Beliefs, Perceptions Of Aging, And Partner Support

  2017cites this paper
• Barriers and facilitators of adjuvant hormone therapy adherence and persistence in women with breast cancer: a systematic review

  2017cites this paper
• Targeting BRK-Positive Breast Cancers with Small-Molecule Kinase Inhibitors.

  2017cites this paper
• Understanding tamoxifen adherence in women with breast cancer: A qualitative study.

  2017cites this paper
• Can demographic, clinical and treatment-related factors available at hormonal therapy initiation predict non-persistence in women with stage I–III breast cancer?

  2017cites this paper
• Prevention of Tamoxifen‐related Nonalcoholic Fatty Liver Disease in Breast Cancer Patients

  2017cites this paper
• Association between tamoxifen treatment and the development of different stages of nonalcoholic fatty liver disease among breast cancer patients.

  2016cites this paper
• Persistence with antidepressant drugs in patients with dementia: a retrospective database analysis.

  2016cites this paper
• Treatment Modification in Young Breast Cancer Patients

  2016cites this paper
• Predictors for discontinuation of adjuvant hormone therapy in breast cancer patients

  2016cites this paper
• Bedeutung der Ovarialsuppression in der endokrinen Therapie des Mammakarzinoms der prämenopausalen Frau Significance of Ovarian Function Suppression in Endocrine Therapy for Breast Cancer in PreMenopausal Women

  2016cites this paper
• Significance of Ovarian Function Suppression in Endocrine Therapy for Breast Cancer in Pre-Menopausal Women

  2016cites this paper
• Age-related differences in persistence in women with breast cancer treated with tamoxifen or aromatase inhibitors in Germany.

  2016cites this paper
• The impact of treatment compliance on fracture risk in women with breast cancer treated with aromatase inhibitors in the United Kingdom

  2016cites this paper
• Significance of Ovarian Function Suppression in Endocrine Therapy for Breast Cancer in Pre-Menopausal Women Bedeutung der Ovarialsuppression in der endokrinen Therapie des Mammakarzinoms der prämenopausalen Frau

  2016cites this paper
• The effect of depression and antidepressants on cost, survival and adherence to hormone therapy in breast cancer

  2016cites this paper
• The impact of tamoxifen brand switch on side effects and patient compliance in hormone receptor positive breast cancer patients.

  2016cites this paper
• The Impact of Access to Cancer Care on Adjuvant Endocrine Therapy Use Among Breast Cancer Survivors in Appalachia

  2015cites this paper
• Ethnic differences in breast cancer outcomes in Aotearoa New Zealand

  2015cites this paper
• Adherence to adjuvant endocrine therapy: is it a factor for ethnic differences in breast cancer outcomes in New Zealand?

  2015cites this paper
• Predictors of Discontinuation of Adjuvant Hormone Therapy in Patients With Breast Cancer.

  2015cites this paper
• The Right Treatment for the Right Patient – Personalised Treatment of Breast Cancer

  2015cites this paper
• Impact of disease management programs on women with breast cancer in Germany

  2015cites this paper
• Comorbidities and Their Management: Potential Impact on Breast Cancer Outcomes.

  2015cites this paper
• Identifying the determinants of adjuvant hormonal therapy medication taking behaviour in women with stages I-III breast cancer: A systematic review and meta-analysis.

  2015cites this paper
• How Women Use Art and Art Therapy to Cope With Breast Cancer: A Systematic Exploration of Published Literature

  2015cites this paper
• Breast Cancer Patients' Experiences and Reflections Regarding Information about Adjuvant Endocrine Therapy and its Side-Effects - A Focus Group Study

  2015cites this paper
• Die richtige Therapie für die richtige Patientin – personalisierte Behandlung des Mammakarzinoms

  2015cites this paper
• Sexual problems during the first 2 years of adjuvant treatment with aromatase inhibitors.

  2014influential citation
• Psychosocial factors in adjuvant hormone therapy for breast cancer: an emerging context for adherence research

  2014influential citation
• Treatment persistence evaluation of tamoxifen and aromatase inhibitors in breast cancer patients in early and late stage disease.

  2014cites this paper
• Real-world patterns of endocrine therapy for metastatic hormone-receptor-positive (HR+)/human epidermal growth factor receptor-2-negative (HER2−) breast cancer patients in the United States: 2002–2012

  2014cites this paper
• Differences in persistency with teriparatide in patients with osteoporosis according to gender and health care provider

  2014cites this paper
• Adherence to Endocrine Therapy in Breast Cancer Adjuvant and Prevention Settings

  2014influential citation
• COMPliance and Arthralgia in Clinical Therapy: the COMPACT trial, assessing the incidence of arthralgia, and compliance within the first year of adjuvant anastrozole therapy.

  2014cites this paper
• Treatment and outcomes in diabetic breast cancer patients

  2014influential citation
• Gender differences in persistency to bisphosphonates in patients with metastatic breast and prostate cancer.

  2014cites this paper
• Depressed mood in breast cancer survivors: associations with physical activity, cancer-related fatigue, quality of life, and fitness level.

  2014cites this paper
• The impact of comorbidity on cancer survival: a review

  2013cites this paper
• Endocrine therapy for breast cancer: a tough pill to swallow.

  2013cites this paper
• Persistence with bisphosphonates in patients with metastatic breast cancer: a retrospective database analysis

  2013cites this paper
• [The importance of adherence to oral therapies in the field of oncology: the example of breast cancer].

  2013cites this paper
• Adherence in tamoxifen therapy after conversion to a rebate pharmaceutical in breast cancer patients in Germany.

  2013cites this paper
• Genomic Testing for Breast Cancer

  2013cites this paper